[ Special series on Gynecological Tumor ]

doi: 10.5732/cjc.014.10278

Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer

José Antonio López-Guerrero, Ignacio Romero, Andrés Poveda

Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, 46009 Valencia, Spain.

[Abstract] Epithelial ovarian cancer (OC) is a common gynecologic malignancy in women. The standard treatment for OC is maximal cytoreductive surgical debulking followed by platinum-based chemotherapy. Despite the high response rate to primary therapy, approximately 85% of patients will develop recurrent ovarian cancer (ROC). This review identifies the clinical use of trabectedin in the treatment algorithm for ROC, with specific emphasis on platinum-sensitive ROC, for which trabectedin in combination with pegylated liposomal doxorubicin has been approved as a treatment protocol. The main mechanisms of action of trabectedin at the cellular level and in the tumor microenvironment is also discussed as bases for identifying biomarkers for selecting patients who may largely benefit from trabectedin-based therapies.

Chinese Journal of Cancer 2015, Volume: 34, Issue 1, Page: 41-49

[ PDF Full-text ]
[ Html full-text ](PubMed Central)
[ PubMed ]
[Google Scholar]

[ More articles of the special series on Gynecological Tumor ]


Cite this article

José Antonio López-Guerrero, Ignacio Romero, Andrés Poveda. Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer. Chin J Cancer. 2015, 34(1):41-49. doi:10.5732/cjc.014.10278


Export citations

EndNote